Sedation and Physiological Effects of Intranasal Dexmedetomidine in Severe COPD
Phase of Trial: Phase IV
Latest Information Update: 10 Feb 2017
Price : $35 *
At a glance
- Drugs Dexmedetomidine (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Adverse reactions
- 12 May 2016 Status changed from recruiting to completed.
- 02 Nov 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.
- 13 Aug 2014 New trial record